You have read all your free articles, to continue reading subscribe to read the rest of this content.
Guard Therapeutics have announced that 134 of the planned 268 patients have been dosed in the global randomized, double-blinded and placebo-controlled Phase 2 clinical trial (AKITA). The AKITA study has been designed to evaluate the kidney-protective effects of the investigational drug RMC-035 inAlready a subscriber Login You have read all…
Karolinska Development's portfolio company Aprea is to evaluate its drug candidate for the treatment of ovarian cancer in a new British study. It is a phase 1b/II study on the pharmaceutical project APR-246, reports Life Science Sweden. The drug candidate is part of a new type of potential cancerAlready a…
Medivir announces the completion of the phase II clinical study of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in patients with early stage CTCL. The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to receive eitheAlready a subscriber Login You have read…
Ultimovacs will participate in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups (ENGOT) and AstraZeneca. The collaborators will conduct a randomized Phase Already a subscriber Login You have read all your free…
